Elite Pharmaceuticals Inc (ELTP)

[Couch]

Total BS.

Elite Pharmaceuticals Announces Positive Top-Line Results From A Pivotal Phase 3 Study For Abuse-Deterrent Opioid ELI-200

http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=79416&GoTopage=1&Category=2163&BzID=2258&t=1955&G=939

Meets Primary and Secondary Endpoints
NORTHVALE, N.J., Oct. 21, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced positive top-line results from the Phase 3 pivotal trial of its lead opioid abuse-deterrent candidate, ELI-200, for the treatment of moderate to severe pain.

The pivotal trial met its primary endpoint (p = 0.001), demonstrating statistical significance that the product provided pain relief following surgery in the treatment group using ELI-200 compared to the placebo group. Secondary endpoint results were consistent with primary findings and included safety measures. There were no serious adverse events or deaths related to ELI-200 reported during the conduct of the trial.